Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Invested Capital (2016 - 2025)

Historic Invested Capital for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $146.8 million.

  • Anika Therapeutics' Invested Capital fell 1838.0% to $146.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.8 million, marking a year-over-year decrease of 1838.0%. This contributed to the annual value of $154.0 million for FY2024, which is 2745.44% down from last year.
  • According to the latest figures from Q3 2025, Anika Therapeutics' Invested Capital is $146.8 million, which was down 1838.0% from $147.7 million recorded in Q2 2025.
  • Anika Therapeutics' Invested Capital's 5-year high stood at $303.7 million during Q2 2021, with a 5-year trough of $146.8 million in Q3 2025.
  • Its 5-year average for Invested Capital is $240.6 million, with a median of $274.0 million in 2023.
  • Its Invested Capital has fluctuated over the past 5 years, first soared by 528.01% in 2021, then plummeted by 3350.34% in 2024.
  • Over the past 5 years, Anika Therapeutics' Invested Capital (Quarter) stood at $291.4 million in 2021, then fell by 2.0% to $285.6 million in 2022, then fell by 25.67% to $212.3 million in 2023, then dropped by 27.45% to $154.0 million in 2024, then decreased by 4.67% to $146.8 million in 2025.
  • Its last three reported values are $146.8 million in Q3 2025, $147.7 million for Q2 2025, and $148.4 million during Q1 2025.